Humana’s (HUM) Neutral Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their neutral rating on shares of Humana (NYSE:HUM) in a research report sent to investors on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a $395.00 target price on the insurance provider’s stock.

Several other research analysts have also weighed in on HUM. Oppenheimer lifted their price objective on shares of Humana from $370.00 to $400.00 and gave the stock an outperform rating in a research note on Thursday, August 1st. Royal Bank of Canada reduced their price objective on shares of Humana from $415.00 to $353.00 and set an outperform rating on the stock in a research note on Thursday, April 25th. Jefferies Financial Group reduced their price objective on shares of Humana from $411.00 to $381.00 and set a buy rating on the stock in a research note on Monday, April 22nd. Piper Sandler assumed coverage on shares of Humana in a research note on Wednesday, June 26th. They issued an overweight rating and a $392.00 price target on the stock. Finally, TD Cowen lifted their price target on shares of Humana from $396.00 to $407.00 and gave the company a buy rating in a research note on Wednesday, July 24th. Thirteen analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Humana has a consensus rating of Hold and a consensus target price of $405.30.

Humana Stock Performance

Shares of NYSE:HUM opened at $353.25 on Monday. The firm’s 50 day simple moving average is $367.68 and its 200 day simple moving average is $346.48. Humana has a fifty-two week low of $298.61 and a fifty-two week high of $530.54. The company has a market capitalization of $42.57 billion, a price-to-earnings ratio of 22.00, a P/E/G ratio of 2.09 and a beta of 0.51. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.67.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, topping the consensus estimate of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The business had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same quarter last year, the firm earned $8.94 EPS. Humana’s quarterly revenue was up 10.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Humana will post 16.14 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be issued a $0.885 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.00%. Humana’s dividend payout ratio (DPR) is presently 22.04%.

Institutional Trading of Humana

Hedge funds and other institutional investors have recently made changes to their positions in the business. Pzena Investment Management LLC increased its holdings in Humana by 538.7% during the second quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock worth $866,250,000 after buying an additional 1,955,375 shares during the last quarter. Davis Selected Advisers increased its holdings in Humana by 16.1% during the second quarter. Davis Selected Advisers now owns 2,311,362 shares of the insurance provider’s stock worth $863,640,000 after buying an additional 321,233 shares during the last quarter. Norges Bank acquired a new position in Humana during the fourth quarter worth $676,800,000. Marshall Wace LLP increased its holdings in Humana by 118.9% during the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock worth $532,564,000 after buying an additional 774,085 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in Humana by 2.1% during the second quarter. Legal & General Group Plc now owns 1,183,985 shares of the insurance provider’s stock worth $442,396,000 after buying an additional 24,842 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.